You searched for "laser trabeculoplasty"
First UK Direct Selective Laser Trabeculoplasty (DSLT) device placed at Moorfields
Following an internationally successful Randomised Controlled Trial (RCT) comparing the Direct Selective Laser Trabeculoplasty (DSLT) with standard SLT, the first ever commercial device in the UK, the ‘Eagle’, has been installed and is in use at Moorfields Eye Hospital in London.Predictors of IOP reduction after SLT
1 December 2016
| Bheemanagouda Patil
|
Glaucoma
|
maximum tolerated therapy, open-angle glaucoma, pre-SLT IOP, predictors for success, selective laser trabeculoplasty
The aim of this study was to identify predictors of intraocular pressure reduction following selective laser trabeculoplasty (SLT) in patients with primary open-angle glaucoma, who are already taking maximally tolerated IOP-lowering medication and need further IOP reduction. In this prospective...
SLT short-term results
1 June 2014
| Lorraine North
|
Glaucoma
The aim of the study was to evaluate the risk of adverse effects and short-term results after 360 degrees selective laser trabeculoplasty (SLT) in glaucoma patients. The authors enrolled 64 eyes of 64 patients all who had poorly controlled primary...
SLT vs. topical treatment with prostaglandin analogues in the management of PACG
1 April 2015
| Lona Jawaheer
|
Glaucoma
Selective laser trabeculoplasty (SLT) has been shown to be useful in the management of primary open angle glaucoma (POAG), but its use in primary angle closure (PAC) / primary angle closure glaucoma (PACG) has yet to be validated. Narayanaswamy et...
BELKIN Vision is pleased to announce FDA clearance for its glaucoma laser, the Eagle device
BELKIN Vision, an innovator in ophthalmic medical solutions, is pleased to announce that the US Food and Drug Administration (FDA) has granted 510(k) clearance for its glaucoma laser, the Eagle device.SLT versus medication for OAG
This paper appraised existing randomised clinical trials (RCTs), which compared selective laser tabeculoplasty (SLT) with medical therapy for open-angle glaucoma (OAG), and performed a systematic review and meta-analysis. A total of 1229 patients in eight trials were included from PubMed,...Carleton Optical Equipment Ltd is recruiting for its expanding Glaucoma team
17 January 2023
|
Recruitment & Personnel
Business Manager - We are looking for an ambitious and capable business manager responsible for the South of England.
The Moorfields and UCL Laser course for ophthalmologists
6 November 2024
Moorfields Eye Hospital and UCL Institute of Ophthalmology are delighted to present this new laser course for ophthalmologists. This full day course will be delivered by Moorfields consultants and senior clinicians. It is designed to enhance both theoretical knowledge and...
Moorfields Education- laser course for ophthalmic healthcare professionals 2025
14 May 2025
Moorfields Eye Hospital and UCL Institute of Ophthalmology are delighted to present the Laser course for ophthalmic healthcare professionals, targeted at clinicians involved in glaucoma and cataract care. The course will involve training in three laser procedures, Selective Laser Trabeculoplasty...
The results of the last survey Aug22
The first question really highlights how we can become enshrined in the way we do things. I genuinely thought that everyone was using a cohesive viscoelastic for their cataract surgery. It was what I was taught, and I believe everyone...Mono vs. multi-therapy in IOP control
1 December 2018
| Eulee Seow
|
Glaucoma
|
baseline pressure, intraocular pressure, multi-therapy, open-angle glaucoma, target pressure, therapy
This randomised control trial studied newly diagnosed glaucoma patients given mono‐ or multi‐therapy regarding differences in initial intraocular pressure (IOP) reduction, target IOP levels reached and influence of untreated baseline IOP on IOP reduction. Patients newly diagnosed with manifest primary...
The National Treatment Centre-Highland
8 September 2023
|
National Treatment Centre-Highland, Andy Pyott, Scotland, Eyecare, Raigmore, NHS Highland
The National Treatment Centre-Highland opened its doors to patients in April 2023. At a cost of £48 million this represented a significant investment by the Scottish Government for the provision of modern eye care for the North of Scotland.